


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9676597/publications.pdf Version: 2024-02-01



LINCL

#	Article	IF	CITATIONS
1	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
2	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. Clinical Cancer Research, 2016, 22, 5223-5228.	3.2	112
3	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of Hematology and Oncology, 2018, 11, 58.	6.9	98
4	Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. Biomedicine and Pharmacotherapy, 2015, 72, 109-112.	2.5	92
5	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies. Cancer Research, 2018, 78, 2457-2462.	0.4	92
6	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene, 2018, 37, 3151-3165.	2.6	90
7	NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Reviews, 2017, 31, 77-92.	2.8	81
8	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	0.6	59
9	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia, 2016, 30, 361-372.	3.3	55
10	The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miRâ€101. Journal of Cellular Physiology, 2019, 234, 13680-13692.	2.0	55
11	Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia, 2019, 33, 1035-1038.	3.3	48
12	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis, 2020, 9, 72.	2.1	48
13	Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation. Acta Pharmacologica Sinica, 2014, 35, 1247-1256.	2.8	45
14	Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal–Regulating Kinase 1 Pathways. Hepatology, 2019, 70, 1099-1118.	3.6	42
15	Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease. Heart Lung and Circulation, 2016, 25, 459-465.	0.2	38
16	Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. European Journal of Heart Failure, 2020, 22, 646-660.	2.9	38
17	Kaempferol Alleviates Angiotensin II-Induced Cardiac Dysfunction and Interstitial Fibrosis in Mice. Cellular Physiology and Biochemistry, 2017, 43, 2253-2263.	1.1	37
18	Saikosaponin A Protects From Pressure Overload-Induced Cardiac Fibrosis via Inhibiting Fibroblast Activation or Endothelial Cell EndMT. International Journal of Biological Sciences, 2018, 14, 1923-1934.	2.6	35

#	Article	IF	CITATIONS
19	Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. Redox Biology, 2018, 18, 211-221.	3.9	35
20	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	0.8	35
21	microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. Oncology Reports, 2016, 36, 3529-3535.	1.2	32
22	NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction. Life Sciences, 2019, 239, 116882.	2.0	32
23	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. Cancer Biology and Therapy, 2019, 20, 31-41.	1.5	32
24	Restless legs syndrome and pregnancy or delivery complications in China: a representative survey. Sleep Medicine, 2016, 17, 158-162.	0.8	31
25	Red Blood Cell Distribution Width and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stenting Era: A Two-Year Cohort Study. PLoS ONE, 2014, 9, e94887.	1.1	29
26	RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	1.4	29
27	Lymphoma associated hemophagocytic syndrome: A single‑center retrospective study. Oncology Letters, 2018, 16, 1275-1284.	0.8	28
28	Fabrication of superparamagnetic nano-silica@ quercetin-encapsulated PLGA nanocomposite: Potential application for cardiovascular diseases. Journal of Photochemistry and Photobiology B: Biology, 2019, 196, 111508.	1.7	28
29	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs, 2020, 38, 1847-1853.	1.2	28
30	Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells. Experimental Cell Research, 2018, 367, 241-250.	1.2	27
31	Effects of vitamin D supplementation as an adjuvant therapy in coronary artery disease patients. Scandinavian Cardiovascular Journal, 2016, 50, 9-16.	0.4	25
32	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus <scp>CHOP</scp> in patients with newly diagnosed peripheral Tâ€cell lymphoma with analysis of biomarkers. British Journal of Haematology, 2017, 178, 772-780.	1.2	25
33	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. Nature Communications, 2019, 10, 4209.	5.8	25
34	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Scientific Reports, 2017, 7, 682.	1.6	24
35	Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open, 2014, 4, e004892-e004892.	0.8	23
36	HMGB1 Is Involved in the Protective Effect of the PPAR <i>α</i> Agonist Fenofibrate against Cardiac Hypertrophy. PPAR Research, 2014, 2014, 1-9.	1.1	23

#	Article	IF	CITATIONS
37	Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. Cancer Medicine, 2019, 8, 3892-3904.	1.3	23
38	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitisâ€like Tâ€cell lymphoma. British Journal of Haematology, 2018, 181, 406-410.	1.2	22
39	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. Journal of Neuro-Oncology, 2018, 140, 427-434.	1.4	22
40	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. Oncologist, 2019, 24, e1123-e1131.	1.9	22
41	C1qTNF-related protein 1 attenuates doxorubicin-induced cardiac injury via activation of AKT. Life Sciences, 2018, 207, 492-498.	2.0	21
42	MYD88 L265P elicits mutation-specific ubiquitination to drive NF- $\hat{I}^{0}B$ activation and lymphomagenesis. Blood, 2021, 137, 1615-1627.	0.6	21
43	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. Oncotarget, 2016, 7, 53808-53819.	0.8	21
44	Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. JAMA Oncology, 2022, 8, 1035.	3.4	21
45	Percutaneous closure of postinfarct muscular ventricular septal defects: A multicenter study in China. Journal of Cardiology, 2014, 64, 285-289.	0.8	20
46	Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 410-418.	1.2	20
47	Hyperoside Suppresses Lipopolysaccharide-induced Inflammation and Apoptosis in Human Umbilical Vein Endothelial Cells. Current Medical Science, 2018, 38, 222-228.	0.7	20
48	TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway. Aging, 2019, 11, 4050-4065.	1.4	20
49	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDCP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. Oncotarget, 2016, 7, 55721-55731.	0.8	19
50	Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment ofÂcentralÂnervous systemÂlymphoma: a retrospective study. Investigational New Drugs, 2022, 40, 650-659.	1.2	19
51	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. Leukemia Research, 2015, 39, 1448-1454.	0.4	18
52	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. Molecular Medicine, 2018, 24, 35.	1.9	18
53	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nature Communications, 2019, 10, 5061.	5.8	18
54	Alpinetin enhances cholesterol efflux and inhibits lipid accumulation in oxidized lowâ€density lipoproteinâ€loaded human macrophages. Biotechnology and Applied Biochemistry, 2015, 62, 840-847.	1.4	16

#	Article	IF	CITATIONS
55	Panax Notoginseng Saponins Protect Cardiac Myocytes Against Endoplasmic Reticulum Stress and Associated Apoptosis Through Mediation of Intracellular Calcium Homeostasis. Frontiers in Pharmacology, 2019, 10, 1013.	1.6	15
56	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. Experimental Cell Research, 2018, 364, 125-132.	1.2	14
57	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. Immunotherapy, 2020, 12, 681-696.	1.0	14
58	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncology Letters, 2016, 11, 693-698.	0.8	13
59	Evaluation of Cardiovascular Risk Factors and Restless Legs Syndrome in Women and Men: A Preliminary Population-Based Study in China. Journal of Clinical Sleep Medicine, 2018, 14, 445-450.	1.4	13
60	<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p> . OncoTargets and Therapy, 2020, Volume 13, 7189-7197.	1.0	13
61	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma Journal of Clinical Oncology, 2020, 38, 3026-3026.	0.8	13
62	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. Blood, 2021, 138, 3829-3829.	0.6	13
63	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2613-2618.	0.6	12
64	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. Oncology Letters, 2016, 12, 4173-4180.	0.8	12
65	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. Oncology Letters, 2017, 13, 1211-1215.	0.8	12
66	Prevalence of CYP17A1 gene mutations in 17α-hydroxylase deficiency in the Chinese Han population. Clinical Hypertension, 2019, 25, 23.	0.7	12
67	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Annals of Hematology, 2021, 100, 1509-1516.	0.8	11
68	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen. Blood, 2019, 134, 463-463.	0.6	11
69	Pretreatment 14â€3â€3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginaseâ€based chemotherapy. Proteomics - Clinical Applications, 2017, 11, 1600111.	0.8	10
70	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers. Scientific Reports, 2018, 8, 1088.	1.6	10
71	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/Tâ€cell lymphoma: A randomized, controlled, openâ€label, multicenter study. International Journal of Cancer, 2021, 148, 1470-1477.	2.3	10
72	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. Oncotarget, 2018, 9, 16213-16219.	0.8	10

#	Article	IF	CITATIONS
73	Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention. Experimental and Therapeutic Medicine, 2016, 11, 2177-2184.	0.8	9
74	<p>Clinical features and prognostic factors of primary bone marrow lymphoma</p> . Cancer Management and Research, 2019, Volume 11, 2553-2563.	0.9	9
75	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. European Journal of Radiology, 2020, 133, 109301.	1.2	9
76	Overexpression of Ubiquitin-Specific Protease 2 (USP2) in the Heart Suppressed Pressure Overload-Induced Cardiac Remodeling. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	9
77	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092382.	1.4	9
78	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Frontiers in Oncology, 2021, 11, 687374.	1.3	9
79	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. Cancer Research and Treatment, 2021, 53, 837-846.	1.3	9
80	Sanggenon C protects against pressure overload-induced cardiac hypertrophy via the calcineurin/NFAT2 pathway. Molecular Medicine Reports, 2017, 16, 5338-5346.	1.1	8
81	Concentration-dependent effects of paeoniflorin on proliferation and apoptosis of vascular smooth muscle cells. Molecular Medicine Reports, 2017, 16, 9567-9572.	1.1	8
82	Analyses and treatment of simultaneous bi‑lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. Oncology Letters, 2018, 16, 6624-6632.	0.8	8
83	Dopamine D4 receptor protected against hyperglycemia-induced endothelial dysfunction via PI3K /eNOS pathway. Biochemical and Biophysical Research Communications, 2019, 518, 554-559.	1.0	8
84	<p>Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study</p> . Cancer Management and Research, 2019, Volume 11, 1363-1372.	0.9	8
85	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/Tâ€cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. Clinical and Translational Science, 2021, 14, 405-411.	1.5	8
86	Therapeutic benefits of <scp>CD</scp> 90â€negative cardiac stromal cells in rats with a 30â€day chronic infarct. Journal of Cellular and Molecular Medicine, 2018, 22, 1984-1991.	1.6	7
87	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. Haematologica, 2020, 105, e107-e110.	1.7	7
88	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. Blood and Lymphatic Cancer: Targets and Therapy, 2019, Volume 9, 33-43.	1.2	6
89	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. Drug Design, Development and Therapy, 2020, Volume 14, 275-284.	2.0	6
90	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. Aging, 2019, 11, 3939-3957.	1.4	6

#	Article	IF	CITATIONS
91	Prognostic value of total bilirubin in patients with angina pectoris undergoing percutaneous coronary intervention. International Journal of Clinical and Experimental Medicine, 2015, 8, 15930-9.	1.3	6
92	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. Frontiers in Endocrinology, 2022, 13, 846357.	1.5	5
93	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. Oncology Letters, 2014, 8, 886-890.	0.8	4
94	Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials. Kidney and Blood Pressure Research, 2019, 44, 384-395.	0.9	4
95	Protection against Doxorubicin-Related Cardiotoxicity by Jaceosidin Involves the Sirt1 Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	4
96	Clinical Characteristics and Contemporary Prognosis of Ventricular Septal Rupture Complicating Acute Myocardial Infarction: A Single-Center Experience. Frontiers in Cardiovascular Medicine, 2021, 8, 679148.	1.1	4
97	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. Cancer Cell International, 2018, 18, 150.	1.8	3
98	A new surgical technique for post-myocardial infarction ventricular septal rupture with hemodynamic instability. Chinese Medical Journal, 2021, 134, 981-983.	0.9	3
99	Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients. Pathology and Oncology Research, 2021, 27, 589662.	0.9	3
100	Clinical analysis of patients with primary and secondary extranodal natural killer/T ell lymphoma of central nervous system. Hematological Oncology, 2023, 41, 267-274.	0.8	3
101	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. Frontiers in Cellular and Infection Microbiology, 2021, 11, 686595.	1.8	3
102	Intervention Effect of Probiotics in Gastric Cancer Patients with Complications of Coronary Heart Disease and Heart Failure. Journal of Oncology, 2021, 2021, 1-6.	0.6	3
103	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. Blood, 2021, 138, 3830-3830.	0.6	3
104	Generation of a human iPSC line ZZUNEUi014-A from a patient with antithrombin deficiency caused by mutation in SERPINC1 gene. Stem Cell Research, 2022, 59, 102646.	0.3	3
105	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. Oncology Letters, 2018, 15, 8034-8038.	0.8	2
106	Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T‑cell lymphoma, nasal type, stages IE and IIE: A SEER‑based study. Oncology Letters, 2019, 18, 3493-3500.	0.8	2
107	An integration-free iPSC line ZZUNEUi008-A derived from dermal fibroblasts of a child with cardiac valvular dysplasia carrying a mutation in FLNA gene. Stem Cell Research, 2020, 47, 101882.	0.3	2
108	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 42-50.	0.3	2

#	Article	IF	CITATIONS
109	Clinicopathological analysis of the hydroa vacciniforme‑like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T‑cell lymphoma. Experimental and Therapeutic Medicine, 2018, 16, 4772-4778.	0.8	1
110	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. Cancer Biology and Medicine, 2021, 19, 1089-1099.	1.4	1
111	Generation of an IPSC line from a patient with hypertrophic cardiomyopathy carrying a mutation in MYH6 gene. Stem Cell Research, 2021, 50, 102138.	0.3	1
112	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial. Blood, 2021, 138, 1368-1368.	0.6	1
113	Linc00883 affects colorectal cancer through miR-577/FKBP14 axis: a novel mechanism for regulating colorectal cancer cell proliferation, invasion, and migration. Cell Cycle, 2022, 21, 2403-2416.	1.3	1
114	<p>Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China</p> . Cancer Management and Research, 2019, Volume 11, 8277-8284.	0.9	0
115	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). Blood, 2016, 128, 2989-2989.	0.6	0
116	Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma. Blood, 2019, 134, 2851-2851.	0.6	0
117	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. Blood, 2019, 134, 2873-2873.	0.6	0
118	Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients Journal of Clinical Oncology, 2020, 38, 8018-8018.	0.8	0
119	Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial. Blood, 2020, 136, 5-5.	0.6	0
120	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. Leukemia and Lymphoma, 2022, , 1-6.	0.6	0
121	Effect of small interference RNA on the acetylcholine-sensitive potassium channel in H9c2 cells. Annals of Clinical and Laboratory Science, 2015, 45, 58-63.	0.2	0